Release Date: 29/07/22 09:39 Summary: Quarterly Activities/Appendix 4C Cash Flow Report Price Sensitive: Yes Download Document 930.87KB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status